NASDAQ: LABTLakewood Amedex Biotherapeutics Inc Stock
$2.50-0.14 (-5.3%)
Updated Jul 27, 2026
LABT Price
$2.50
Fair Value Price
N/A
Market Cap
$1.75M
52 Week Low
$1.66
52 Week High
$98.20
P/E
N/A
P/B
-0.62x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.07
Operating Cash Flow
N/A
Beta
-2.4
Next Earnings
Aug 28, 2026
Ex-Dividend
N/A
Next Dividend
N/A
LABT Overview
This biopharmaceutical company is dedicated to developing innovative antimicrobial therapies. Its array of anti-infective products is designed to tackle specific viral conditions, including avian influenza, Epstein-Barr Virus (EBV), and hepatitis B and C. Established by Roderic Dale on July 11, 2006, the firm maintains its principal office in Bradenton, Florida.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine LABT's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
LABT
Ranked#281 of 462
Ranked#281 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $255.43 | A | |
| $11.13 | A | |
| $8.21 | A |
Be the first to know about important LABT news, forecast changes, insider trades & much more!
LABT News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LABT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LABT's short-term liabilities ($3.03M) exceed its short-term assets ($50.63k)
Short-term Liabilities Financials
LABT's short-term assets ($50.63k) exceed its long-term liabilities ($10.30k)
Long-term Liabilities Financials
LABT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
There are 30 more LABT due diligence checks available for Premium users.
Valuation
LABT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.62x
Industry
5.36x
LABT's financial health
Profit margin
Revenue
$0.0
Net Income
-$923.3k
Profit Margin
0%
Assets to liabilities
Assets
$196.3k
Liabilities
$3.0M
Debt to equity
-1.07
LABT's short-term liabilities ($3.03M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LABT's short-term assets ($50.63k) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LABT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
LABT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$349.7k
Investing
$0.0
Financing
$125.0k
LABT vs Biotech Stocks
Lakewood Amedex Biotherapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.